Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Detect develops a point-of-care molecular diagnostics platform for women's health applications. The company brings laboratory-quality testing capabilities to clinical settings closer to patients.
2 investors
Dia Beta Labs is a drug discovery and development company focused on diabetes and obesity research. The company leverages academic expertise and scientific innovation in these therapeutic areas.
2 investors
Diag-Nose.io develops precision diagnostics and therapies for respiratory diseases including asthma, COPD, and sinusitis by combining nasal microsampling, proteomics, and machine learning to analyze airway biology. The company serves respiratory specialists, biotech companies, pharmaceutical firms, and researchers.
2 investors
Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds. It brings together clinical researchers and pharmaceutical development experts to advance early-stage candidates for mood and related disorders.
2 investors
DIANA Biotechnologies is a Czech biotech company that sells products and services to the life sciences research market through a distributed network of regional distributors and scientific marketplaces.
2 investors
A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally. The company conducts research and development, collaborates with scientists and biotech innovators, and has reached millions of patients through its innovative therapeutic approaches.
2 investors
Digma Medical develops the Endoscopic Gastrointestinal Ablation Device (EGAD), a minimally invasive therapy using a console and single-use catheter for contactless, imaging-guided ablation of esophageal mucosal tissue, initially targeting Barrett's Esophagus. The device is designed for use in standard GI endoscopy suites and serves gastroenterology clinicians treating pre-cancerous and other GI pathologies.
2 investors
Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function. It operates in the biotechnology and pharmaceutical space focused on therapeutics for people with impaired bladder and bowel control.
2 investors
Diligent provides a centralized vendor management platform for clinical trial sponsors to discover, qualify, and oversee vendors, aiming to reduce qualification timelines and mitigate risk. It also maintains VendorBase, a global database where clinical research vendors can get qualified and gain exposure to sponsors seeking partnerships.
2 investors
DINYA DNA builds an enzymatic "Exponential Synthesis" platform that directly synthesizes long, complex double-stranded DNA up to 5kb from a pre-built material library without oligo assembly, delivering custom sequences in 3-10 days. It serves scientists through an Early Access synthesis service, planned to launch in 2026, in the synthetic biology and gene synthesis space.
2 investors
DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols. It serves specialty chemical, nutraceutical, and industrial customers seeking sustainable, cost-competitive alternatives to conventional chemical supply chains.
2 investors
Caidya is a global full-service clinical research organization (CRO) that supports biopharmaceutical companies with clinical trial design, execution, and patient recruitment across more than 40 countries. It provides patient-centric clinical trial solutions and high-quality data delivery across core therapeutic areas.
2 investors
Particella, Inc. (formerly DNAlite Therapeutics) is a preclinical biotechnology company developing an oral lipid nanoparticle platform to deliver nucleic acids, such as mRNA, to the intestinal epithelium. It focuses on oral mRNA medicines.
2 investors
DNA Script develops enzymatic DNA synthesis technology, offered through its SYNTAX platform, that lets labs produce high-quality ssDNA oligos in-house and overnight. It serves research and life sciences customers including CROs, core facilities, biotech and pharma companies, and government agencies.
2 investors
2 investors
dNovo develops direct reprogramming technology to convert skin, blood, or fat cells into new stem cells, targeting age-related stem cell depletion. The company aims to address aging through cellular regeneration for consumers.
2 investors
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation. The company leverages a proprietary drug discovery platform and two decades of expertise to create first-in-class and best-in-class drug candidates.
2 investors
Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.
2 investors
Dot Ingredients develops particle surfactant technology to support climate change mitigation efforts. The company is a research-focused organization based in Auckland, New Zealand with connections to Auckland University of Technology.
2 investors
Dotomics builds foundation models for biology using AI and machine learning. The company serves researchers and organizations in the biotechnology and life sciences sectors.
2 investors
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment. Its lead candidate, sirpiglenastat (DRP-104), is in clinical trials for advanced solid tumors including KEAP1/NFE2L2-altered non-small cell lung cancer.
2 investors
Dreamfold engineers proteins as therapeutic medicines, using generative AI models that reason over protein sequence and structure to enable potent, localized immune modulation with minimal off-target effects.
2 investors
Droplet Biosciences develops cancer diagnostics with a focus on liquid biopsy and precision oncology. The company works in the molecular diagnostics space for cancer detection and personalized medicine.
2 investors
Drug Hunter publishes educational content, molecule case studies, patent highlights, and analysis on small molecule and biologic drug discovery for medicinal chemists and pharmaceutical R&D professionals. The site covers therapeutic targets, clinical-stage molecules, and drug development strategies across oncology, neurology, and other disease areas.
2 investors